María Vallet-Regí,Juan L. Paris
Abstract:Mesoporous silica nanoparticles have attracted much attention in recent years as drug and gene delivery systems for biomedical applications. Among their most beneficial features for biomedicine, we can highlight their biocompatibility and their outstanding textural properties, which provide a great loading capacity for many types of cargos. In the context of cancer nanomedicine, combination therapy and gene transfection/silencing have recently been highlighted as two of its most promising fields. In this review, we aim to provide an overview of the different small molecule drug-nucleic acid co-delivery combinations that have been developed using mesoporous silica nanoparticles as carriers. By carefully selecting the chemotherapeutic drug and nucleic acid cargos to be co-delivered by mesoporous silica nanoparticles, different therapeutic goals can be achieved by overcoming resistance mechanisms, combining different cytotoxic mechanisms, or providing an additional antiangiogenic effect. The examples here presented highlight the great promise of this type of strategies for the development of future therapeutics.
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is: how to use mesoporous silica nanoparticles (MSNs) as carriers to achieve the co - delivery of drugs and nucleic acids in order to improve the efficacy of cancer treatment. Specifically, by carefully selecting the chemotherapeutic drugs and nucleic acid cargos to be co - delivered, resistance mechanisms can be overcome, different cytotoxic mechanisms can be combined, or additional anti - angiogenic effects can be provided, thereby achieving different treatment goals.
### Summary of the Core Issues in the Paper
1. **Improving the Efficacy of Cancer Treatment**:
- By co - delivering chemotherapeutic drugs and nucleic acids, a synergistic effect can be achieved, enhancing the treatment effect.
- Overcome the drug - resistance problem that may occur in single - therapy.
2. **Overcoming Delivery Barriers**:
- Nucleic acids (such as siRNA, plasmid DNA, etc.) cannot cross the cell membrane on their own and require an effective carrier to protect and deliver them to specific sub - cellular locations.
- Ensure that nanoparticles can effectively escape the endosomal compartment and enter the cytoplasm or nucleus to perform their functions.
3. **Developing Smart - Responsive Nanoscale Systems**:
- Utilize the porous structure and modifiable properties of MSNs to design smart - responsive nanoscale systems that are sensitive to specific stimuli (such as pH, redox, enzymes, light, magnetic fields, etc.) to achieve controlled release.
4. **Exploring Multiple Co - Delivery Strategies**:
- Surface Functionalization: By modifying positively - charged groups (such as amino groups) on the MSN surface to interact with negatively - charged nucleic acids to achieve delivery.
- Polycationic Coating: Use polycations (such as PEI) to coat MSNs, which not only protects nucleic acids from degradation but also enhances cell uptake.
- Macroporous MSNs: Prepare MSNs with large pore sizes, directly load nucleic acids into the pores, while reserving the surface for other chemical modifications.
### Key Formulas
- **pH - Responsive Release**:
\[
\text{Acidic pH} \rightarrow \text{Cleavage of disulfide bonds}
\]
In an acidic environment, disulfide bonds break, resulting in the release of drugs or nucleic acids.
- **Redox - Responsive Release**:
\[
\text{Reducing environment} \rightarrow \text{Cleavage of disulfide bonds}
\]
In a reducing environment, disulfide bonds break, promoting the release of drugs or nucleic acids.
Through these strategies, the paper demonstrates the great potential of MSNs in cancer treatment, especially in the co - delivery of drugs and nucleic acids, providing an important reference for the development of future therapies.